Why the study?
Does monoclonal antibody VIS410 improve outcomes in adults with uncomplicated influenza A infection?
Population
Adults with uncomplicated influenza A infection
Comparison
Monoclonal antibody VIS410 vs placebo
Design
Randomized, double-blind, phase-2, placebo-controlled study
Authors
Loading...
Supports further development of VIS410 for influenza A; extends randomized evidence for monoclonal antibodies targeting viral hemagglutinin.
Does monoclonal antibody VIS410 improve outcomes in adults with uncomplicated influenza A infection?
Hershberger et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: